Balance of yin and yang: Ubiquitylation-mediated regulation of p53 and c-Myc

Neoplasia

Volumn 8, Issue 8, 2006, Pages 630-644

  Dai, Mu Shui ^a   Jin, Yetao ^a   Gallegos, Jayme R ^a   Lu, Hua ^a,b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

c Myc; Oncogenesis; p53; Ubiquitylation; Yin and yang

Indexed keywords

ARF PROTEIN; MYC PROTEIN; NUCLEAR PROTEIN; ONCOPROTEIN; PROTEIN MDM2; PROTEIN P53; S PHASE KINASE ASSOCIATED PROTEIN 2; TUMOR SUPPRESSOR PROTEIN; UBIQUITIN PROTEIN LIGASE; UBIQUITIN PROTEIN LIGASE E3; UBIQUITIN;

CANCER INHIBITION; CARCINOGENESIS; CELL GROWTH; CELL PROLIFERATION; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN METABOLISM; PROTEIN PROCESSING; PROTEIN STABILITY; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; TRANSACTIVATION; UBIQUITINATION; CELL TRANSFORMATION; METABOLISM; PHYSIOLOGY;

CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; HUMANS; PROTO-ONCOGENE PROTEINS C-MYC; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITIN; UBIQUITIN-PROTEIN LIGASE COMPLEXES;

EID: 33748522684     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.06334     Document Type: Review

References (245)

1. Hahn WC and Weinberg RA (2002). Modelling the molecular circuitry of cancer. Nat Rev Cancer 2, 331-341.
2. Olive KP, Tuveson DA, Ruhe ZC, Yin B, Willis NA, Bronson RT, Crowley D, and Jacks T (2004). Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 119, 847-860.
3. Lang GA, Iwakuma T, Suh YA, Liu G, Rao VA, Parant JM, Valentin-Vega YA, Terzian T, Caldwell LC, Strong LC, et al. (2004). Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 119, 861-872.
4. Srivastava S, Zou ZQ, Pirollo K, Blattner W, and Chang EH (1990). Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature 348, 747-749.
5. Malkin D, Li FP, Strong LC, Fraumeni JF Jr., Nelson CE, Kim DH, Kassel J, Gryka MA, Bischoff FZ, Tainsky MA, et al. (1990). Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250, 1233-1238.
6. Hollstein M, Sidransky D, Vogelstein B, and Harris CC (1991). p53 mutations in human cancers. Science 253, 49-53.
7. Soussi T, Dehouche K, and Beroud C (2000). p53 website and analysis of p53 gene mutations in human cancer: forging a link between epidemiology and carcinogenesis. Hum Mutat 15, 105-113.
8. Vogelstein B, Lane D, and Levine AJ (2000). Surfing the p53 network. Nature 408, 307-310.
9. Vousden KH (2002). Activation of the p53 tumor suppressor protein. Biochim Biophys Acta 1602, 47-59.
10. Oren M (2003). Decision making by p53: life, death and cancer. Cell Death Differ 10, 431-442.
11. Prives C (1998). Signaling to p53: breaking the MDM2-p53 circuit. Cell 95, 5-8.
12. Dumont P, Leu JI, Della Pietra AC III, George DL, and Murphy M (2003). The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 33, 357-365.
13. Mihara M, Erster S, Zaika A, Petrenko O, Chittenden T, Pancoska P, and Moll UM (2003). p53 has a direct apoptogenic role at the mitochondria. Mol Cell 11, 577-590.
14. Chipuk JE, Kuwana T, Bouchier-Hayes L, Droin NM, Newmeyer DD, Schuler M, and Green DR (2004). Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science 303, 1010-1014.
15. Ford JM (2005). Regulation of DNA damage recognition and nucleotide excision repair: another role for p53. Mutat Res 577, 195-202.
16. Pickart CM (2000). Ubiquitin in chains. Trends Biochem Sci 25, 544-548.
17. Flick K, Ouni I, Wohlschlegel JA, Capati C, McDonald WH, Yates JR, and Kaiser P (2004). Proteolysis-independent regulation of the transcription factor Met4 by a single Lys 48-linked ubiquitin chain. Nat Cell Biol 6, 634-641.
18. Cahilly-Snyder L, Yang-Feng T, Francke U, and George DL (1987). Molecular analysis and chromosomal mapping of amplified genes isolated from a transformed mouse 3T3 cell line. Somat Cell Mol Genet 13, 235-244.
19. Iwakuma T and Lozano G (2003). MDM2, an introduction. Mol Cancer Res 1, 993-1000.
20. Chen J, Marechal V, and Levine AJ (1993). Mapping of the p53 and mdm-2 interaction domains. Mol Cell Biol 13, 4107-4114.
21. Oliner JD, Pietenpol JA, Thiagalingam S, Gyuris J, Kinzler KW, and Vogelstein B (1993). Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature 362, 857-860.
22. Kawai H, Wiederschain D, and Yuan ZM (2003). Critical contribution of the MDM2 acidic domain to p53 ubiquitination. Mol Cell Biol 23, 4939-4947.
23. Meulmeester E, Frenk R, Stad R, de Graaf P, Marine JC, Vousden KH, and Jochemsen AG (2003). Critical role for a central part of Mdm2 in the ubiquitylation of p53. Mol Cell Biol 23, 4929-4938.
24. Argentini M, Barboule N, and Wasylyk B (2001). The contribution of the acidic domain of MDM2 to p53 and MDM2 stability. Oncogene 20, 1267-1275.
25. Zhu Q, Yao J, Wani G, Wani MA, and Wani AA (2001). Mdm2 mutant defective in binding p300 promotes ubiquitination but not degradation of p53: evidence for the role of p300 in integrating ubiquitination and proteolysis. J Biol Chem 276, 29695-29701.
26. Fang S, Jensen JP, Ludwig RL, Vousden KH, and Weissman AM (2000). Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53. J Biol Chem 275, 8945-8951.
27. Freedman DA and Levine AJ (1998). Nuclear export is required for degradation of endogenous p53 by MDM2 and human papillomavirus E6. Mol Cell Biol 18, 7288-7293.
28. Roth J, Dobbelstein M, Freedman DA, Shenk T, and Levine AJ (1998). Nucleocytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein. EMBO J 17, 554-564.
29. Lohrum MA, Ashcroft M, Kubbutat MH, and Vousden KH (2000). Contribution of two independent MDM2-binding domains in p14(ARF) to p53 stabilization. Curr Biol 10, 539-542.
30. Momand J, Zambetti GP, Olson DC, George D, and Levine AJ (1992). The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69, 1237-1245.
31. Lu H, Lin J, Chen J, and Levine AJ (1994). The regulation of p53-mediated transcription and the roles of hTAFII31 and mdm-2. Harvey Lect 90, 81-93.
32. Honda R, Tanaka H, and Yasuda H (1997). Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett 420, 25-27.
33. Boyd SD, Tsai KY, and Jacks T (2000). An intact HDM2 RING-finger domain is required for nuclear exclusion of p53. Nat Cell Biol 2, 563-568.
34. Geyer RK, Yu ZK, and Maki CG (2000). The MDM2 RING-finger domain is required to promote p53 nuclear export. Nat Cell Biol 2, 569-573.
35. Lohrum MA, Woods DB, Ludwig RL, Balint E, and Vousden KH (2001). C-terminal ubiquitination of p53 contributes to nuclear export. Mol Cell Biol 21, 8521-8532.
36. Tao W and Levine AJ (1999). Nucleocytoplasmic shuttling of oncoprotein Hdm2 is required for Hdm2-mediated degradation of p53. Proc Natl Acad Sci USA 96, 3077-3080.
37. Minsky N and Oren M (2004). The RING domain of Mdm2 mediates histone ubiquitylation and transcriptional repression. Mol Cell 16, 631-639.
38. Jin Y, Zeng SX, Dai MS, Yang XJ, and Lu H (2002). MDM2 inhibits PCAF (p300/CREB-binding protein-associated factor)-mediated p53 acetylation. J Biol Chem 277, 30838-30843.
39. Perry ME, Piette J, Zawadzki JA, Harvey D, and Levine AJ (1993). The mdm-2 gene is induced in response to UV light in a p53-dependent manner. Proc Natl Acad Sci USA 90, 11623-11627.
40. Barak Y, Juven T, Haffner R, and Oren M (1993). mdm2 expression is induced by wild type p53 activity. EMBO J 12, 461-468.
41. Picksley SM and Lane DP (1993). The p53-mdm2 autoregulatory feedback loop: a paradigm for the regulation of growth control by p53? Bioessays 15, 689-690.
42. Wu X, Bayle JH, Olson D, and Levine AJ (1993). The p53-mdm-2 autoregulatory feedback loop. Genes Dev 7, 1126-1132.
43. Jones SN, Roe AE, Donehower LA, and Bradley A (1995). Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature 378, 206-208.
44. Montes de Oca Luna R, Wagner DS, and Lozano G (1995). Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 378, 203-206.
45. Stommel JM and Wahl GM (2004). Accelerated MDM2 auto-degradation induced by DNA-damage kinases is required for p53 activation. EMBO J 23, 1547-1556.
46. Shirangi TR, Zaika A, and Moll UM (2002). Nuclear degradation of p53 occurs during down-regulation of the p53 response after DNA damage. FASEB J 16, 420-422.
47. Joseph TW, Zaika A, and Moll UM (2003). Nuclear and cytoplasmic degradation of endogenous p53 and HDM2 occurs during downregulation of the p53 response after multiple types of DNA damage. FASEB J 17, 1622-1630.
48. Rodriguez MS, Desterro JM, Lain S, Lane DP, and Hay RT (2000). Multiple C-terminal lysine residues target p53 for ubiquitin-proteasome-mediated degradation. Mol Cell Biol 20, 8458-8467.
49. Grossman SR, Deato ME, Brignone C, Chan HM, Kung AL, Tagami H, Nakatani Y, and Livingston DM (2003). Polyubiquitination of p53 by a ubiquitin ligase activity of p300. Science 300, 342-344.
50. Grossman SR, Perez M, Kung AL, Joseph M, Mansur C, Xiao ZX, Kumar S, Howley PM, and Livingston DM (1998). p300/MDM2 complexes participate in MDM2-mediated p53 degradation. Mol Cell 2, 405-415.
51. Shvarts A, Steegenga WT, Riteco N, van Laar T, Dekker P, Bazuine M, van Ham RC, van der Houven van Oordt W, Hateboer G, van der Eb AJ, et al. (1996). MDMX: a novel p53-binding protein with some functional properties of MDM2. EMBO J 15, 5349-5357.
52. Linares LK, Hengstermann A, Ciechanover A, Muller S, and Scheffner M (2003). HdmX stimulates Hdm2-mediated ubiquitination and degradation of p53. Proc Natl Acad Sci USA 100, 12009-12014.
53. Migliorini D, Denchi EL, Danovi D, Jochemsen A, Capillo M, Gobbi A, Helin K, Pelicci PG, and Marine JC (2002). Mdm4 (Mdmx) regulates p53-induced growth arrest and neuronal cell death during early embryonic mouse development. Mol Cell Biol 22, 5527-5538.
54. Parant J, Chavez-Reyes A, Little NA, Yan W, Reinke V, Jochemsen AG, and Lozano G (2001). Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53. Nat Genet 29, 92-95.
55. Pan Y and Chen J (2003). MDM2 promotes ubiquitination and degradation of MDMX. Mol Cell Biol 23, 5113-5121.
56. de Graaf P, Little NA, Ramos YF, Meulmeester E, Letteboer SJ, and Jochemsen AG (2003). Hdmx protein stability is regulated by the ubiquitin ligase activity of Mdm2. J Biol Chem 278, 38315-38324.
57. Brignone C, Bradley KE, Kisselev AF, and Grossman SR (2004). A postubiquitination role for MDM2 and hHR23A in the p53 degradation pathway. Oncogene 23, 4121-4129.
58. Leng RP, Lin Y, Ma W, Wu H, Lemmers B, Chung S, Parant JM, Lozano G, Hakem R, and Benchimol S (2003). Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation. Cell 112, 779-791.
59. Dornan D, Wertz I, Shimizu H, Arnott D, Frantz GD, Dowd P, O'Rourke K, Koeppen H, and Dixit VM (2004). The ubiquitin ligase COP1 is a critical negative regulator of p53. Nature 429, 86-92.
60. Scheffner M, Huibregtse JM, Vierstra RD, and Howley PM (1993). The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 75, 495-505.
61. Dyson N, Howley PM, Munger K, and Harlow E (1989). The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 243, 934-937.
62. Werness BA, Levine AJ, and Howley PM (1990). Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 248, 76-79.
63. Rolfe M, Beer-Romero P, Glass S, Eckstein J, Berdo I, Theodoras A, Pagano M, and Draetta G (1995). Reconstitution of p53-ubiquitinylation reactions from purified components: the role of human ubiquitin-conjugating enzyme UBC4 and E6-associated protein (E6AP). Proc Natl Acad Sci USA 92, 3264-3268.
64. Chen D, Kon N, Li M, Zhang W, Qin J, and Gu W (2005). ARF-BP1/Mule is a critical mediator of the ARF tumor suppressor. Cell 121, 1071-1083.
65. Esser C, Scheffner M, and Hohfeld J (2005). The chaperone-associated ubiquitin ligase CHIP is able to target p53 for proteasomal degradation. J Biol Chem 280, 27443-27448.
66. Bargonetti J, Manfredi JJ, Chen X, Marshak DR, and Prives C (1993). A proteolytic fragment from the central region of p53 has marked sequence-specific DNA-binding activity when generated from wild-type but not from oncogenic mutant p53 protein. Genes Dev 7, 2565-2574.
67. Hinds PW, Finlay CA, Quartin RS, Baker SJ, Fearon ER, Vogelstein B, and Levine AJ (1990). Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells: a comparison nomas of the "hot spot" mutant phenotypes. Cell Growth Differ 1, 571-580.
68. Gannon JV, Greaves R, Iggo R, and Lane DP (1990). Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO J 9, 1595-1602.
69. Rainwater R, Parks D, Anderson ME, Tegtmeyer P, and Mann K (1995). Role of cysteine residues in regulation of p53 function. Mol Cell Biol 15, 3892-3903.
70. Stephen CW and Lane DP (1992). Mutant conformation of p53. Precise epitope mapping using a filamentous phage epitope library. J Mol Biol 225, 577-583.
71. Deshaies RJ (1999). SCF and Cullin/Ring H2- based ubiquitin ligases. Annu Rev Cell Dev Biol 15, 435-467.
72. Querido E, Blanchette P, Yan Q, Kamura T, Morrison M, Boivin D, Kaelin WG, Conaway RC, Conaway JW, and Branton PE (2001). Degradation of p53 by adenovirus E4orf6 and E1B55K proteins occurs radation via a novel mechanism involving a Cullin-containing complex. Genes Dev 15, 3104-3117.
73. Blanchette P, Cheng CY, Yan Q, Ketner G, Ornelles DA, Dobner T, Conaway RC, Conaway JW, and Branton PE (2004). Both BC-box motifs of adenovirus protein E4orf6 are required to efficiently assemble an E3 ligase complex that degrades p53. Mol Cell Biol 24, 9619-9629.
74. Querido E, Morrison MR, Chu-Pham-Dang H, Thirlwell SW, Boivin D, and Branton PE (2001). Identification of three functions of the adenovirus e4orf6 protein that mediate p53 degradation by the E4orf6-E1B55K complex. J Virol 75, 699-709.
75. Andrews P, He YJ, and Xiong Y (2006). Cytoplasmic localized ubiquitin ligase cullin 7 binds to p53 and promotes cell growth by antagonizing p53 function. Oncogene 25, March 20 [Epub ahead of print].
76. Li M, Chen D, Shiloh A, Luo J, Nikolaev AY, Qin J, and Gu W (2002). Deubiquitination of p53 by HAUSP is an important pathway for p53 stabilization. Nature 416, 648-653.
77. Cummins JM, Rago C, Kohli M, Kinzler KW, Lengauer C, and Vogelstein B (2004). Tumour suppression: disruption of HAUSP gene stabilizes p53. Nature 428, 486-487.
78. Meulmeester E, Maurice MM, Boutell C, Teunisse AF, Ovaa H, Abraham TE, Dirks RW, and Jochemsen AG (2005). Loss of HAUSP-mediated deubiquitination contributes to DNA damage-induced destabilization of Hdmx and Hdm2. Mol Cell 18, 565-576.
79. Li M, Brooks CL, Kon N, and Gu W (2004). A dynamic role of HAUSP in the p53-Mdm2 pathway. Mol Cell 13, 879-886.
80. Appella E and Anderson CW (2001). Post-translational modifications and activation of p53 by genotoxic stresses. Eur J Biochem 268, 2764-2772.
81. Meek DW and Knippschild U (2003). Posttranslational modification of MDM2. Mol Cancer Res 1, 1017-1026.
82. Jin Y, Dai MS, Lu SZ, Xu Y, Luo Z, Zhao Y, and Lu H (2006). 14-3-3gamma binds to MDMX that is phosphorylated by UV-activated Chk1, resulting in p53 activation. EMBO J 25, 1207-1218.
83. LeBron C, Chen L, Gilkes DM, and Chen J (2006). Regulation of MDMX nuclear import and degradation by Chk2 and 14-3-3. EMBO J 25, 1196-1206.
84. Okamoto K, Kashima K, Pereg Y, Ishida M, Yamazaki S, Nota A, Teunisse A, Migliorini D, Kitabayashi I, Marine JC, et al. (2005). DNA damage-induced phosphorylation of MdmX at serine 367 activates p53 by targeting MdmX for Mdm2-dependent degradation. Mol Cell Biol 25, 9608-9620.
85. Eisenman RN (2001). Deconstructing myc. Genes Dev 15, 2023-2030.
86. Pelengaris S, Khan M, and Evan G (2002). c-MYC: more than just a matter of life and death. Nat Rev Cancer 2, 764-776.
87. Sakamuro D and Prendergast GC (1999). New Myc-interacting proteins: a second Myc network emerges. Oncogene 18, 2942-2954.
88. Amati B, Dalton S, Brooks MW, Littlewood TD, Evan GI, and Land H (1992). Transcriptional activation by the human c-Myc oncoprotein in yeast requires interaction with Max. Nature 359, 423-426.
89. Adhikary S and Eilers M (2005). Transcriptional regulation and transformation by Myc proteins. Nat Rev Mol Cell Biol 6, 635-645.
90. Luscher B and Larsson LG (1999). The basic region/helix-loop-helix/ leucine zipper domain of Myc proto-oncoproteins: function and regulation. Oncogene 18, 2955-2966.
91. Ayer DE, Kretzner L, and Eisenman RN (1993). Mad: a heterodimeric partner for Max that antagonizes Myc transcriptional activity. Cell 72, 211-222.
92. Ayer DE and Eisenman RN (1993). A switch from Myc:Max to Mad:Max heterocomplexes accompanies monocyte/macrophage differentiation. Genes Dev 7, 2110-2119.
93. Wanzel M, Herold S, and Eilers M (2003). Transcriptional repression by Myc. Trends Cell Biol 13, 146-150.
94. Staller P, Peukert K, Kiermaier A, Seoane J, Lukas J, Karsunky H, Moroy T, Bartek J, Massague J, Hanel F, et al. (2001). Repression of p15INK4b expression by Myc through association with Miz-1. Nat Cell Biol 3, 392-399.
95. Seoane J, Pouponnot C, Staller P, Schader M, Eilers M, and Massague J (2001). TGFbeta influences Myc, Miz-1 and Smad to control the CDK inhibitor p15INK4b. Nat Cell Biol 3, 400-408.
96. Seoane J, Le HV, and Massague J (2002). Myc suppression of the p21(Cip1) Cdk inhibitor influences the outcome of the p53 response to DNA damage. Nature 419, 729-734.
97. Herold S, Wanzel M, Beuger V, Frohme C, Beul D, Hillukkala T, Syvaoja J, Saluz HP, Haenel F, and Eilers M (2002). Negative regulation of the mammalian UV response by Myc through association with Miz-1. Mol Cell 10, 509-521.
98. Grandori C, Gomez-Roman N, Felton-Edkins ZA, Ngouenet C, Galloway DA, Eisenman RN, and White RJ (2005). c-Myc binds to human ribosomal DNA and stimulates transcription of rRNA genes by RNA polymerase I. Nat Cell Biol 7, 311-318.
99. Grewal SS, Li L, Orian A, Eisenman RN, and Edgar BA (2005). Myc-dependent regulation of ribosomal RNA synthesis during dependent Drosophila development. Nat Cell Biol 7, 295-302.
100. Arabi A, Wu S, Ridderstrale K, Bierhoff H, Shiue C, Fatyol K, Fahlen S, Hydbring P, Soderberg O, Grummt I, et al. (2005). c-Myc associates with ribosomal DNA and activates RNA polymerase I transcription. Nat Cell Biol 7, 303-310.
101. Davis AC, Wims M, Spotts GD, Hann SR, and Bradley A (1993). A null c-myc mutation causes lethality before 10.5 days of gestation in homozygotes and reduced fertility in heterozygous female mice. Genes Dev 7, 671-682.
102. Trumpp A, Refaeli Y, Oskarsson T, Gasser S, Murphy M, Martin GR, and Bishop JM (2001). c-Myc regulates mammalian body size by controlling cell number but not cell size. Nature 414, 768-773.
103. de Alboran IM, O'Hagan RC, Gartner F, Malynn B, Davidson L, Rickert R, Rajewsky K, DePinho RA, and Alt FW (2001). Analysis of C-MYC function in normal cells via conditional gene-targeted mutation. Immunity 14, 45-55.
104. Ryan KM and Birnie GD (1997). Cell-cycle progression is not essential for c-Myc to block differentiation. Oncogene 14, 2835-2843.
105. La Rocca SA, Crouch DH, and Gillespie DA (1994). c-Myc inhibits myogenic differentiation and myoD expression by a mechanism which can be dissociated from cell transformation. Oncogene 9, 3499-3508.
106. Nilsson JA and Cleveland JL (2003). Myc pathways provoking cell suicide and cancer. Oncogene 22, 9007-9021.
107. Evan GI, Wyllie AH, Gilbert CS, Littlewood TD, Land H, Brooks M, Waters CM, Penn LZ, and Hancock DC (1992). Induction of apoptosis in fibroblasts by c-myc protein. Cell 69, 119-128.
108. Cole MD (1986). The myc oncogene: its role in transformation and differentiation. Annu Rev Genet 20, 361-384.
109. Nesbit CE, Tersak JM, and Prochownik EV (1999). MYC oncogenes and human neoplastic disease. Oncogene 18, 3004-3016.
110. Spencer CA and Groudine M (1991). Control of c-myc regulation in normal and neoplastic cells. Adv Cancer Res 56, 1-48.
111. Mougneau E, Lemieux L, Rassoulzadegan M, and Cuzin F (1984). Biological activities of logical v-myc and rearranged c-myc oncogenes in rat fibroblast cells in culture. Proc Natl Acad Sci USA 81, 5758-5762.
112. Kohl NE and Ruley HE (1987). Role of c-myc in the transformation of REF52 cells by viral and cellular oncogenes. Oncogene 2, 41-48.
113. Adams JM, Harris AW, Pinkert CA, Corcoran LM, Alexander WS, Cory S, Palmiter RD, and Brinster RL (1985). The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 318, 533-538.
114. Pelengaris S, Littlewood T, Khan M, Elia G, and Evan G (1999). Reversible activation of c-Myc in skin: induction of a complex neoplastic versible phenotype by a single oncogenic lesion. Mol Cell 3, 565-577.
115. Felsher DW and Bishop JM (1999). Reversible tumorigenesis by MYC in hematopoietic lineages. Mol Cell 4, 199-207.
116. Pelengaris S, Khan M, and Evan GI (2002). Suppression of Myc-induced apoptosis in beta cells exposes multiple oncogenic properties induced of Myc and triggers carcinogenic progression. Cell 109, 321-334.
117. Kubbutat MH, Jones SN, and Vousden KH (1997). Regulation of p53 stability by Mdm2. Nature 387, 299-303.
118. Haupt Y, Maya R, Kazaz A, and Oren M (1997). Mdm2 promotes the rapid degradation of p53. Nature 387, 296-299.
119. Hann SR and Eisenman RN (1984). Proteins encoded by the human c-myc oncogene: differential expression in neoplastic cells. Mol Cell Biol 4, 2486-2497.
120. Ciechanover A, DiGiuseppe JA, Bercovich B, Orian A, Richter JD, Schwartz AL, and Brodeur GM (1991). Degradation of nuclear onco-proteins by the ubiquitin system proteins in vitro vitro. Proc Natl Acad Sci USA 88, 139-143.
121. Flinn EM, Busch CM, and Wright AP (1998). myc boxes, which are conserved in myc family proteins, are signals for protein degradation via the proteasome. Mol Cell Biol 18, 5961-5969.
122. Gross-Mesilaty S, Reinstein E, Bercovich B, Tobias KE, Schwartz AL, Kahana C, and Ciechanover A (1998). Basal and human papillomavirus E6 oncoprotein-induced degradation of Myc proteins by the ubiquitin pathway. Proc Natl Acad Sci USA 95, 8058-8063.
123. Salghetti SE, Muratani M, Wijnen H, Futcher B, and Tansey WP (2000). Functional overlap of sequences that activate transcription and signal ubiquitin-mediated proteolysis. Proc Natl Acad Sci USA 97, 3118-3123.
124. Muratani M and Tansey WP (2003). How the ubiquitin-proteasome system controls transcription. Nat Rev Mol Cell Biol 4, 192-201.
125. Salghetti SE, Kim SY, and Tansey WP (1999). Destruction of Myc by ubiquitin-mediated proteolysis: cancer-associated and transforming mutations stabilize Myc. EMBO J 18, 717-726.
126. Gregory MA and Hann SR (2000). c-Myc proteolysis by the ubiquitin-proteasome pathway: stabilization of c-Myc in Burkitt's lymphoma cells. Mol Cell Biol 20, 2423-2435.
127. Spotts GD, Patel SV, Xiao Q, and Hann SR (1997). Identification of downstream-initiated c-Myc proteins which are dominant-negative inhibitors of transactivation by full-length c-Myc proteins. Mol Cell Biol 17, 1459-1468.
128. von der Lehr N, Johansson S, Wu S, Bahram F, Castell A, Cetinkaya C, Hydbring P, Weidung I, Nakayama K, Nakayama KI, et al. (2003). The F-box protein Skp2 participates in c-Myc proteosomal degradation and acts as a cofactor for c-Myc-regulated transcription. Mol Cell 11, 1189-1200.
129. von der Lehr N, Johansson S, and Larsson LG (2003). Implication of the ubiquitin/proteasome system in Myc-regulated transcription. Cell Cycle 2, 403-407.
130. Kim SY, Herbst A, Tworkowski KA, Salghetti SE, and Tansey WP (2003). Skp2 regulates Myc protein stability and activity. Mol Cell 11, 1177-1188.
131. Moberg KH, Mukherjee A, Veraksa A, Artavanis-Tsakonas S, and Hariharan IK (2004). The Drosophila F box protein archipelago regulates dMyc protein levels in vivo. Curr Biol 14, 965-974.
132. Yada M, Hatakeyama S, Kamura T, Nishiyama M, Tsunematsu R, Imaki H, Ishida N, Okumura F, Nakayama K, and Nakayama KI (2004). Phosphorylation- dependent degradation of c-Myc is mediated by the F-box protein Fbw7. EMBO J 23, 2116-2125.
133. Welcker M, Orian A, Jin J, Grim JE, Harper JW, Eisenman RN, and Clurman BE (2004). The Fbw7 tumor suppressor regulates glycogen synthase kinase 3 phosphorylation-dependent c-Myc protein degradation. Proc Natl Acad Sci USA 101, 9085-9090.
134. Welcker M, Orian A, Grim JE, Eisenman RN, and Clurman BE (2004). A nucleolar isoform of the Fbw7 ubiquitin ligase regulates c-Myc and cell size. Curr Biol 14, 1852-1857.
135. Adhikary S, Marinoni F, Hock A, Hulleman E, Popov N, Beier R, Bernard S, Quarto M, Capra M, Goettig S, et al. (2005). The ubiquitin ligase HectH9 regulates transcriptional activation by Myc and is essential for tumor cell proliferation. Cell 123, 409-421.
136. Shieh SY, Ikeda M, Taya Y, and Prives C (1997). DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 91, 325-334.
137. Kapoor M, Hamm R, Yan W, Taya Y, and Lozano G (2000). Cooperative phosphorylation at multiple sites is required to activate p53 in response to UV radiation. Oncogene 19, 358-364.
138. Hirao A, Kong YY, Matsuoka S, Wakeham A, Ruland J, Yoshida H, Liu D, Elledge SJ, and Mak TW (2000). DNA damage-induced activation of p53 by the checkpoint kinase Chk2. Science 287, 1824-1827.
139. Chehab NH, Malikzay A, Appel M, and Halazonetis TD (2000). Chk2/hCds1 functions as a DNA damage checkpoint in G(1) by stabilizing p53. Genes Dev 14, 278-288.
140. Gregory MA, Qi Y, and Hann SR (2003). Phosphorylation by glycogen synthase kinase-3 controls c-myc proteolysis and subnuclear localization. J Biol Chem 278, 51606-51612.
141. Chang DW, Claassen GF, Hann SR, and Cole MD (2000). The c-Myc transactivation domain is a direct modulator of apoptotic versus proliferative signals. Mol Cell Biol 20, 4309-4319.
142. Lutterbach B and Hann SR (1994). Hierarchical phosphorylation at N-terminal transformation-sensitive sites in c-Myc protein is regulated by mitogens and in mitosis. Mol Cell Biol 14, 5510-5522.
143. Sears R, Nuckolls F, Haura E, Taya Y, Tamai K, and Nevins JR (2000). Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. Genes Dev 14, 2501-2514.
144. Oster SK, Ho CS, Soucie EL, and Penn LZ (2002). The myc oncogene: MarvelouslY Complex. Adv Cancer Res 84, 81-154.
145. Sears R, Leone G, DeGregori J, and Nevins JR (1999). Ras enhances Myc protein stability. Mol Cell 3, 169-179.
146. Yeh E, Cunningham M, Arnold H, Chasse D, Monteith T, Ivaldi G, Hahn WC, Stukenberg PT, Shenolikar S, Uchida T, et al. (2004). A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells. Nat Cell Biol 6, 308-318.
147. Axelson H, Henriksson M, Wang Y, Magnusson KP, and Klein G (1995). The amino-terminal phosphorylation sites of C-MYC are frequently mutated in Burkitt's lymphoma lines but not in mouse plasmacytomas and rat immunocytomas. Eur J Cancer 31A, 2099-2104.
148. Albert T, Urlbauer B, Kohlhuber F, Hammersen B, and Eick D (1994). Ongoing mutations in the N-terminal domain of c-Myc affect transactivation in Burkitt's lymphoma cell lines. Oncogene 9, 759-763.
149. Bhatia K, Huppi K, Spangler G, Siwarski D, Iyer R, and Magrath I (1993). Point mutations in the c-Myc transactivation domain are common in Burkitt's lymphoma and mouse plasmacytomas. Nat Genet 5, 56-61.
150. Bahram F, von der Lehr N, Cetinkaya C, and Larsson LG (2000). c-Myc hot spot mutations in lymphomas result in inefficient ubiquitination and decreased proteasome-mediated turnover. Blood 95, 2104-2110.
151. Hemann MT, Bric A, Teruya-Feldstein J, Herbst A, Nilsson JA, Cordon-Cardo C, Cleveland JL, Tansey WP, and Lowe SW (2005). Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants. Nature 436, 807-811.
152. Minella AC and Clurman BE (2005). Mechanisms of tumor suppression by the SCF(Fbw7). Cell Cycle 4, 1356-1359.
153. Park J, Kunjibettu S, McMahon SB, and Cole MD (2001). The ATM-related domain of TRRAP is required for histone acetyltransferase recruitment and Myc-dependent oncogenesis. Genes Dev 15, 1619-1624.
154. McMahon SB, Wood MA, and Cole MD (2000). The essential cofactor TRRAP recruits the histone acetyltransferase hGCN5 to c-Myc. Mol Cell Biol 20, 556-562.
155. Frank SR, Schroeder M, Fernandez P, Taubert S, and Amati B (2001). Binding of c-Myc to chromatin mediates mitogen-induced acetylation of histone H4 and gene activation. Genes Dev 15, 2069-2082.
156. Bouchard C, Dittrich O, Kiermaier A, Dohmann K, Menkel A, Eilers M, and Luscher B (2001). Regulation of cyclin D2 gene expression by the Myc/Max/Mad network: Myc-dependent TRRAP recruitment and histone acetylation at the cyclin D2 promoter. Genes Dev 15, 2042-2047.
157. Wood MA, McMahon SB, and Cole MD (2000). An ATPase/helicase complex is an essential cofactor for oncogenic transformation by c-Myc. Mol Cell 5, 321-330.
158. Chi Y, Huddleston MJ, Zhang X, Young RA, Annan RS, Carr SA, and Deshaies RJ (2001). Negative regulation of Gcn4 and Msn2 transcription factors by Srb10 cyclin-dependent kinase. Genes Dev 15, 1078-1092.
159. Salghetti SE, Caudy AA, Chenoweth JG, and Tansey WP (2001). Regulation of transcriptional activation domain function by ubiquitin. Science 293, 1651-1653.
160. Ferdous A, Gonzalez F, Sun L, Kodadek T, and Johnston SA (2001). The 19S regulatory particle of the proteasome is required for efficient transcription elongation by RNA polymerase II. Mol Cell 7, 981-991.
161. Gonzalez F, Delahodde A, Kodadek T, and Johnston SA (2002). Recruitment of a 19S proteasome subcomplex to an activated promoter. Science 296, 548-550.
162. Itahana K, Bhat KP, Jin A, Itahana Y, Hawke D, Kobayashi R, and Zhang Y (2003). Tumor suppressor ARF degrades B23, a nucleolar protein involved in ribosome biogenesis and cell proliferation. Mol Cell 12, 1151-1164.
163. Sugimoto M, Kuo ML, Roussel MF, and Sherr CJ (2003). Nucleolar Arf tumor suppressor inhibits ribosomal RNA processing. Mol Cell 11, 415-424.
164. Zindy F, Eischen CM, Randle DH, Kamijo T, Cleveland JL, Sherr CJ, and Roussel MF (1998). Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev 12, 2424-2433.
165. Zhang Y and Xiong Y (2001). Control of p53 ubiquitination and nuclear export by MDM2 and ARF. Cell Growth Differ 12, 175-186.
166. Zhang Y, Xiong Y, and Yarbrough WG (1998). ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 92, 725-734.
167. Palmero I, Pantoja C, and Serrano M (1998). p19 ARF links the tumour suppressor p53 to Ras. Nature 395, 125-126.
168. Weber JD, Taylor LJ, Roussel MF, Sherr CJ, and Bar-Sagi D (1999). Nucleolar Arf sequesters Mdm2and activates p53. Nat Cell Biol 1, 20-26.
169. Tao W and Levine AJ (1999). P19(ARF) stabilizes p53 by blocking nucleo-cytoplasmic shuttling of Mdm2. Proc Natl Acad Sci USA 96, 6937-6941.
170. Honda R and Yasuda H (1999). Association of p19(ARF) with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53. EMBO J 18, 22-27.
171. ARF. Oncogene 20, 5543-5547.
172. Randerson-Moor JA, Harland M, Williams S, Cuthbert-Heavens D, Sheridan E, Aveyard J, Sibley K, Whitaker L, Knowles M, Bishop JN, et al. (2001). A germline deletion of p14(ARF) but not CDKN2A in a melanoma-neural system tumour syndrome family. Hum Mol Genet 10, 55-62.
173. Kamijo T, Bodner S, van de Kamp E, Randle DH, and Sherr CJ (1999). Tumor spectrum in ARF-deficient mice. Cancer Res 59, 2217-2222.
174. ARF. Cell 91, 649-659.
175. Zhong Q, Gao W, Du F, and Wang X (2005). Mule/ARF-BP1, a BH3-only E3 ubiquitin ligase, catalyzes the polyubiquitination of Mcl-1 and regulates apoptosis. Cell 121, 1085-1095.
176. Gu J, Ren K, Dubner R, and Iadarola MJ (1994). Cloning of a DNA binding protein that is a tyrosine kinase substrate and recognizes an upstream initiator-like sequence in the promoter of the preprodynorphin gene. Brain Res Mol Brain Res 24, 77-88.
177. Brooks CL and Gu W (2006). p53 ubiquitination: Mdm2 and beyond. Mol Cell 21, 307-315.
178. Datta A, Nag A, Pan W, Hay N, Gartel AL, Colamonici O, Mori Y, and Raychaudhuri P (2004). Myc-ARF (alternate reading frame) interaction inhibits the functions of Myc. J Biol Chem 279, 36698-36707.
179. ARF directly and differentially controls the functions of c-Myc independently of p53. Nature 431, 712-717.
180. Strezoska Z, Pestov DG, and Lau LF (2000). Bop1 is a mouse WD40 repeat nucleolar protein involved in 28S and 5.8S RRNA processing and 60S ribosome biogenesis. Mol Cell Biol 20, 5516-5528.
181. Strezoska Z, Pestov DG, and Lau LF (2002). Functional inactivation of the mouse nucleolar protein Bop1 inhibits multiple steps in pre-rRNA processing and blocks cell cycle progression. J Biol Chem 277, 29617-29625.
182. Pestov DG, Strezoska Z, and Lau LF (2001). Evidence of p53-dependent cross-talk between ribosome biogenesis and the cell cycle: effects of nucleolar protein Bop1 on G(1)/S transition. Mol Cell Biol 21, 4246-4255.
183. Ashcroft M, Taya Y, and Vousden KH (2000). Stress signals utilize multiple pathways to stabilize p53. Mol Cell Biol 20, 3224-3233.
184. Sulic S, Panic L, Barkic M, Mercep M, Uzelac M, and Volarevic S (2005). Inactivation of S6 ribosomal protein gene in T lymphocytes activates a
185. Volarevic S, Stewart MJ, Ledermann B, Zilberman F, Terracciano L, Montini E, Grompe M, Kozma SC, and Thomas G (2000). Proliferation, but not growth, blocked by conditional deletion of 40S ribosomal protein S6. Science 288, 2045-2047.
186. Ashcroft M, Kubbutat MH, and Vousden KH (1999). Regulation of p53 function and stability by phosphorylation. Mol Cell Biol 19, 1751-1758.
187. Dai MS and Lu H (2004). Inhibition of MDM2-mediated p53 ubiquitination and degradation by ribosomal protein L5. J Biol Chem 279, 44475-44482.
188. Dai MS, Zeng SX, Jin Y, Sun XX, David L, and Lu H (2004). Ribosomal protein L23 activates p53 by inhibiting MDM2 function in response to ribosomal perturbation but not to translation inhibition. Mol Cell Biol 24, 7654-7668.
189. Zhang Y, Wolf GW, Bhat K, Jin A, Allio T, Burkhart WA, and Xiong Y (2003). Ribosomal protein L11 negatively regulates oncoprotein MDM2 and mediates a p53-dependent ribosomal-stress checkpoint pathway. Mol Cell Biol 23, 8902-8912.
190. Lohrum MA, Ludwig RL, Kubbutat MH, Hanlon M, and Vousden KH (2003). Regulation of HDM2 activity by the ribosomal protein L11. Cancer Cell 3, 577-587.
191. Jin A, Itahana K, O'Keefe K, and Zhang Y (2004). Inhibition of HDM2 and activation of p53 by ribosomal protein L23. Mol Cell Biol 24, 7669-7680.
192. Bhat KP, Itahana K, Jin A, and Zhang Y (2004). Essential role of ribosomal protein L11 in mediating growth inhibition-induced p53 activation. EMBO J 23, 2402-2412.
193. ARF on the levels of ubiquitinated p53 and Mdm2 in vivo vivo. Oncogene 20, 4972-4983.
194. Szebeni A and Olson MO (1999). Nucleolar protein B23 has molecular chaperone activities. Protein Sci 8, 905-912.
195. Savkur RS and Olson MO (1998). Preferential cleavage in pre-ribosomal RNA byprotein B23 endoribonuclease. Nucleic Acids Res 26, 4508-4515.
196. Kurki S, Peltonen K, Latonen L, Kiviharju TM, Ojala PM, Meek D, and Laiho M (2004). Nucleolar protein NPM interacts with HDM2 and protects tumor suppressor protein p53 from HDM2-mediated degradation. Cancer Cell 5, 465-475.
197. Colombo E, Marine JC, Danovi D, Falini B, and Pelicci PG (2002). Nucleophosmin regulates the stability and transcriptional activity of p53. Nat Cell Biol 4, 529-533.
198. Rubbi CP and Milner J (2003). Disruption of the nucleolus mediates stabilization of p53 in response to DNA damage and other stresses. EMBO J 22, 6068-6077.
199. Chan PK, Qi Y, Amley J, and Koller CA (1996). Quantitation of the nucleophosmin/B23-translocation using imaging analysis. Cancer Lett 100, 191-197.
200. Moss T (2004). At the crossroads of growth control; making ribosomal RNA. Curr Opin Genet Dev 14, 210-217.
201. Rudra D and Warner JR (2004). What better measure than ribosome synthesis? Genes Dev 18, 2431-2436.
202. Andersen JS, Lyon CE, Fox AH, Leung AK, Lam YW, Steen H, Mann M, and Lamond AI (2002). Directed proteomic analysis of the human nucleolus. Curr Biol 12, 1-11.
203. Scherl A, Coute Y, Deon C, Calle A, Kindbeiter K, Sanchez JC, Greco A, Hochstrasser D, and Diaz JJ (2002). Functional proteomic analysis of human nucleolus. Mol Biol Cell 13, 4100-4109.
204. White RJ (2005). RNA polymerases I and III, growth control and cancer. Nat Rev Mol Cell Biol 6, 69-78.
205. Ruggero D and Pandolfi PP (2003). Does the ribosome translate cancer? Nat Rev Cancer 3, 179-192.
206. Menssen A and Hermeking H (2002). Characterization of the c-MYC-regulated transcriptome by SAGE: identification and analysis of c-MYC target genes. Proc Natl Acad Sci USA 99, 6274-6279.
207. Coller HA, Grandori C, Tamayo P, Colbert T, Lander ES, Eisenman RN, and Golub TR (2000). Expression analysis with oligonucleotide microarrays reveals that MYC regulates genes involved in growth, cell cycle, arrays signaling, and adhesion. Proc Natl Acad Sci USA 97, 3260-3265.
208. Boon K, Caron HN, van Asperen R, Valentijn L, Hermus MC, van Sluis P, Roobeek I, Weis I, Voute PA, Schwab M, et al. (2001). N-myc enhances the expression of a large set of genes functioning in ribosome biogenesis and protein synthesis. EMBO J 20, 1383-1393.
209. Guo QM, Malek RL, Kim S, Chiao C, He M, Ruffy M, Sanka K, Lee NH, Dang CV, and Liu ET (2000). Identification of c-myc responsive genes using rat cDNA microarray. Cancer Res 60, 5922-5928.
210. Gomez-Roman N, Grandori C, Eisenman RN, and White RJ (2003). Direct activation of RNA polymerase III transcription by c-Myc. Nature 421, 290-294.
211. Amsterdam A, Sadler KC, Lai K, Farrington S, Bronson RT, Lees JA, and Hopkins N (2004). Many ribosomal protein genes are cancer genes in zebrafish. PLoS Biol 2, E139.
212. Finlay CA (1993). The mdm-2 oncogene can overcome wild-type p53 suppression of transformed cell growth. Mol Cell Biol 13, 301-306.
213. Fakharzadeh SS, Trusko SP, and George DL (1991). Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. EMBO J 10, 1565-1569.
214. Dworakowska D, Jassem E, Jassem J, Peters B, Dziadziuszko R, Zylicz M, Jakobkiewicz-Banecka J, Kobierska-Gulida G, Szymanowska A, Skokowski J, et al. (2004). MDM2 gene amplification: a new independent factor of adverse prognosis in non-small cell lung cancer (NSCLC). Lung Cancer 43, 285-295.
215. Bueso-Ramos CE, Yang Y, deLeon E, McCown P, Stass SA, and Albitar M (1993). The human MDM-2 oncogene is overexpressed in leukemias. Blood 82, 2617-2623.
216. Cordon-Cardo C, Latres E, Drobnjak M, Oliva MR, Pollack D, Woodruff JM, Marechal V, Chen J, Brennan MF, and Levine AJ (1994). Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res 54, 794-799.
217. Deb SP (2003). Cell cycle regulatory functions of the human oncoprotein MDM2. Mol Cancer Res 1, 1009-1016.
218. Momand J, Jung D, Wilczynski S, and Niland J (1998). The MDM2 gene amplification database. Nucleic Acids Res 26, 3453-3459.
219. Watanabe T, Ichikawa A, Saito H, and Hotta T (1996). Overexpression of the MDM2 oncogene in leukemia and lymphoma. Leuk Lymphoma 21, 391-397 (color plate XVI following 5).
220. Fbw7 ubiquitin ligase. Science 294, 173-177.
221. Moberg KH, Bell DW, Wahrer DC, Haber DA, and Hariharan IK (2001). Archipelago regulates Cyclin E levels in Drosophila and is mutated in human cancer cell lines. Nature 413, 311-316.
222. Strohmaier H, Spruck CH, Kaiser P, Won KA, Sangfelt O, and Reed SI (2001). Human F-box protein hCdc4 targets cyclin E for proteolysis and is mutated in a breast cancer cell line. Nature 413, 316-322.
223. Fbw7 antagonizes apoptotic JNK signaling. Science 303, 1374-1378.
224. Wei W, Jin J, Schlisio S, Harper JW, and Kaelin WG Jr (2005). The v-Jun point mutation allows c-Jun to escape GSK3-dependent recognition and destruction by the Fbw7 ubiquitin ligase. Cancer Cell 8, 25-33.
225. Wu G, Lyapina S, Das I, Li J, Gurney M, Pauley A, Chui I, Deshaies RJ, and Kitajewski J (2001). SEL-10 is an inhibitor of notch signaling that targets notch for ubiquitin-mediated protein degradation. Mol Cell Biol 21, 7403-7415.
226. Oberg C, Li J, Pauley A, Wolf E, Gurney M, and Lendahl U (2001). The Notch intracellular domain is ubiquitinated and negatively regulated by the mammalian Sel-10 homolog. J Biol Chem 276, 35847-35853.
227. Spruck CH, Strohmaier H, Sangfelt O, Muller HM, Hubalek M, Muller-Holzner E, Marth C, Widschwendter M, and Reed SI (2002). hCDC4 gene mutations in endometrial cancer. Cancer Res 62, 4535-4539.
228. Rajagopalan H, Jallepalli PV, Rago C, Velculescu VE, Kinzler KW, Vogelstein B, and Lengauer C (2004). Inactivation of hCDC4 can cause chromosomal instability. Nature 428, 77-81.
229. Knuutila S, Aalto Y, Autio K, Bjorkqvist AM, El-Rifai W, Hemmer S, Huhta T, Kettunen E, Kiuru-Kuhlefelt S, Larramendy ML, et al. (1999). DNA copy number losses in human neoplasms. Am J Pathol 155, 683-694.
230. Mao JH, Perez-Losada J, Wu D, Delrosario R, Tsunematsu R, Nakayama KI, Brown K, Bryson S, and Balmain A (2004). Fbxw7/Cdc4 is a p53-dependent, haploinsufficient tumour suppressor gene. Nature 432, 775-779.
231. Spruck CH, Won KA, and Reed SI (1999). Deregulated cyclin E induces chromosome instability. Nature 401, 297-300.
232. Donnellan R and Chetty R (1999). Cyclin E in human cancers. FASEB J 13, 773-780.
233. Erlanson M and Landberg G (2001). Prognostic implications of p27 and cyclin E protein contents in malignant lymphomas. Leuk Lymphoma 40, 461-470.
234. Porter PL, Malone KE, Heagerty PJ, Alexander GM, Gatti LA, Firpo EJ, Daling JR, and Roberts JM (1997). Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat Med 3, 222-225.
235. Bortner DM and Rosenberg MP (1997). Induction of mammary gland hyperplasia and carcinomas in transgenic mice expressing human cyclin E. Mol Cell Biol 17, 453-459.
236. Sutterluty H, Chatelain E, Marti A, Wirbelauer C, Senften M, Muller U, and Krek W (1999). p45SKP2 promotes p27Kip1 degradation and induces S phase in quiescent cells. Nat Cell Biol 1, 207-214.
237. Carrano AC, Eytan E, Hershko A, and Pagano M (1999). SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nat Cell Biol 1, 193-199.
238. Nakayama K, Nagahama H, Minamishima YA, Miyake S, Ishida N, Hatakeyama S, Kitagawa M, Iemura S, Natsume T, and Nakayama KI (2004). Skp2-mediated degradation of p27 regulates progression into mitosis. Dev Cell 6, 661-672.
239. Latres E, Chiarle R, Schulman BA, Pavletich NP, Pellicer A, Inghirami G, and Pagano M (2001). Role of the F-box protein Skp2 in lymphomagenesis. Proc Natl Acad Sci USA 98, 2515-2520.
240. Shim EH, Johnson L, Noh HL, Kim YJ, Sun H, Zeiss C, and Zhang H (2003). Expression of the F-box protein SKP2 induces hyperplasia, dysplasia, and low-grade carcinoma in the mouse prostate. Cancer Res 63, 1583-1588.
241. Fotouhi N and Graves B (2005). Small molecule inhibitors of p53/MDM2 interaction. Curr Top Med Chem 5, 159-165.
242. Fischer PM and Lane DP (2004). Small-molecule inhibitors of the p53 suppressor HDM2: have protein-protein interactions come of age as drug targets? Trends Pharmacol Sci 25, 343-346.
243. Yang Y, Ludwig RL, Jensen JP, Pierre SA, Medaglia MV, Davydov IV, Safiran YJ, Oberoi P, Kenten JH, Phillips AC, et al. (2005). Small molecule inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells. Cancer Cell 7, 547-559.
244. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, Kong N, Kammlott U, Lukacs C, Klein C, et al. (2004). In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303, 844-848.
245. Dai MS, Shi D, Jin Y, Sun XX, Zhang Y, Grossman SR, and Lu H. (2006) Regulation of the MDM2-p53 pathway by ribosomal protein L11 involves a post-ubiquitination mechanism. J Biol Chem 281, Jun 27, [Epub ahead of print].